Cancer clinical trials in the region Auvergne-Rhône-Alpes
494 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT06312137
#2023-508012-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Brain tumors / Central nervous system tumors
#NCT06809322
#2024-519404-27-00
Required histologic types
Gliomas
Required histologic sub types
Astrocytoma grade II
Astrocytoma grade III
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required previous treatments
Surgery
Radiochemotherapy
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Brain tumors / Central nervous system tumors
#NCT05902169
#2023-505829-14-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery
Immunotherapy
Chemotherapy
Radiotherapy
Excluded genetic anomalies
BRAF
IDH1/2
NTRK-1/2/3
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CarThera
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie C (Sensible au platine naive de traitement par Parpi
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
10 recruiting sites
Eli Lilly et compagnie
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie A (Résistant au platine)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie B (Sensible au platine avec traitement antérieur par Parpi)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at localized stage
Chemotherapy
Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie
Phase 3
Brain tumors / Central nervous system tumors
#NCT05904119
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery
Radiochemotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Brain tumors / Central nervous system tumors
#NCT05476939
#2014-001929-32
Phase inclusion DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy
Radiotherapy
32 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Brain tumors / Central nervous system tumors
#NCT05476939
#2014-001929-32
Phase inclusion - gliomes diffus de la ligne médiane non-DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy
Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lymphoma
#NCT06006117
#2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Targeted therapy
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)